Gary K. Lee - Feb 9, 2024 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: Chief Scientific Officer
Signature: /s/ Matthew Lang, as Attorney-in-Fact
Stock symbol: LYEL
Transactions as of: Feb 9, 2024
Transactions value $: $0
Form type: 4
Date filed: 2/13/2024, 08:22 PM
Previous filing: Nov 20, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LYEL	Common Stock	Award	$0	+40K	+314.96%	$0.00	52.7K	Feb 9, 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LYEL	Stock Option (right to buy)	Award	$0	+400K		$0.00	400K	Feb 9, 2024	Common Stock	400K	$1.80	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2	Includes 4,702 shares acquired on November 18, 2022, 6,205 shares acquired on May 18, 2023 and 1,793 shares acquired on November 17, 2023 under the Issuer's 2021 Employee Stock Purchase Plan.
F3	12.5% of the option shares shall vest on August 9, 2024, with the remaining option shares to vest in equal monthly installments over the following forty-two months.